Smart hedge funds don't wait for headlines. They hunt for inflection points before they become obvious. ImmunityBio Inc. (IBRX) just handed them one on a silver platter.

The biotech company's stock has rocketed nearly 96% year-to-date, but here's what actually matters: On Thursday, ImmunityBio reported roughly $113 million in 2025 revenue. That's a jaw-dropping 700% year-over-year increase, the kind of number that transforms speculative positioning into validated conviction.

The Commercial Ramp That Hedge Funds Anticipated

The headline number is impressive, but drill into the details and you'll see why certain funds moved early. Fourth quarter revenue alone came in at $38.3 million, surging 431% year-over-year. The driver? Anktiva, the company's lead oncology therapy, which is scaling faster than most cancer treatments at a comparable stage.

In biotech, velocity is everything. Plenty of drugs make it to market only to languish with disappointing uptake. Anktiva is doing the opposite, transitioning the story from binary trial risk to commercial execution and actual demand. That shift is precisely what sophisticated investors watch for.

Citadel and Renaissance Positioned Before the Proof

This revenue explosion didn't surprise everyone. Renaissance Technologies initiated its ImmunityBio position in the quarter ending September 30, 2025. During that same period, Ken Griffin's Citadel Advisors boosted its stake by more than 40%. These weren't reactive trades chasing momentum. They were calculated bets on commercialization speed outpacing expectations.

For these funds, the question wasn't whether Anktiva would reach the market. It was whether revenue would scale faster than the Street anticipated. The latest results suggest their thesis is playing out.

What This Means for Retail Investors

Trading around $5 per share, ImmunityBio still carries a speculative biotech valuation. But 700% revenue growth changes the conversation. When early institutional positioning aligns with genuine sales acceleration, markets typically shift from debating potential to pricing momentum. And once that transition kicks in, volatility tends to work both ways, often aggressively to the upside.